Document is current
Any future updates will be listed below
-
Authors
Xia, Bingqing
Shen, Xurui
He, Yang
Pan, Xiaoyan
Liu, Feng-Liang
Wang, Yi
Yang, Feipu
Fang, Sui
Wu, Yan https://orcid.org/0000-0002-0928-6127
Duan, Zilei
Zuo, Xiaoli
Xie, Zhuqing
Jiang, Xiangrui
Xu, Ling
Chi, Hao
Li, Shuangqu
Meng, Qian
Zhou, Hu https://orcid.org/0000-0001-7006-4737
Zhou, Yubo
Cheng, Xi https://orcid.org/0000-0003-3735-645X
Xin, Xiaoming
Jin, Lin
Zhang, Hai-Lin
Yu, Dan-Dan
Li, Ming-Hua
Feng, Xiao-Li
Chen, Jiekai https://orcid.org/0000-0001-5168-7074
Jiang, Hualiang https://orcid.org/0000-0003-0656-6315
Xiao, Gengfu
Zheng, Yong-Tang https://orcid.org/0000-0001-5469-0324
Zhang, Lei-Ke https://orcid.org/0000-0002-2593-2571
Shen, Jingshan https://orcid.org/0000-0001-9679-9934
Li, Jia
Gao, Zhaobing
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81773707, 31700732)
- License Information
-
More Information
Article History
Received: 15 February 2021
Accepted: 13 May 2021
First Online: 10 June 2021
Competing interests
: The authors declare no competing interests. Shanghai Institute of Materia Medica has applied for Chinese patents which cover the compounds BE-12, 30–33. Compounds BE-12, 30–33 are available from J.S. under a material transfer agreement with Shanghai Institute of Materia Medica.
